PTC Therapeutics, Inc. - PTCT STOCK NEWS

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in two upcoming investor conferences. Management will present at the Cowen Virtual 42nd Annual Health Care Conference on March 7, 2022, at 1:30 p.m. ET, and at the Barclays Global Healthcare Conference on March 17, 2022, at 8 a.m. ET. Both presentations will be available via live webcast on the company’s website, where they will also be archived for 30 days post-event. PTC is committed to developing innovative medicines for rare disorders.

PTC Therapeutics (NASDAQ: PTCT) reported significant advancements in their pipeline and financial performance for Q4 and full-year 2021. Total revenues reached $538.6 million, up from $380.8 million in 2020, with DMD product revenues surpassing $400 million. Key milestones include a $25 million royalty from Evrysdi, marking it as the leading SMA therapy in the U.S. However, the company faced a net loss of $523.9 million in 2021 and expects total revenues of $700-$750 million in 2022, indicating strong growth alongside ongoing R&D investments.

PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call on February 22, 2022, at 4:30 p.m. ET to discuss fourth quarter and year-end 2021 financial results.

Interested parties can participate by calling (877) 303-9216 in the U.S. or (973) 935-8152 internationally. A live webcast will also be available on the company's investor website, with a replay accessible for 30 days post-call.

PTC Therapeutics announced that the FDA has granted priority review for its Evrysdi (risdiplam) to treat pre-symptomatic infants under 2 months with spinal muscular atrophy (SMA). If approved, Evrysdi will be the first at-home treatment for this vulnerable group. Interim data from the RAINBOWFISH study showed that 80% of treated infants achieved key motor milestones within 12 months. The company emphasizes the need for early treatment in SMA cases, reinforcing the significance of Evrysdi in improving patients' lives.

PTC Therapeutics (NASDAQ: PTCT) has announced the launch of the eighth annual STRIVE™ awards program to support initiatives for the Duchenne muscular dystrophy community. Grants will be awarded to patient advocacy organizations focusing on Innovation or Transition to Adulthood. The application process is open until March 18, 2022, with recipients announced in September. The STRIVE program has funded over 35 initiatives across 20 countries since its inception, enhancing awareness and support for Duchenne patients.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on Jan. 7, 2022, the approval of non-statutory stock options for 26 new employees, totaling 18,255 shares, along with 10,675 restricted stock units (RSUs). These awards aim to incentivize new hires as part of their employment compensation, following NASDAQ's inducement grant exception. All stock options have an exercise price of $38.10 per share and vest over four years, contingent on continued service. This initiative reflects PTC's commitment to attracting talent for its rare disorder therapies.

PTC Therapeutics, Inc. (NASDAQ: PTCT) has launched its 2022 Talent Pipeline Program, a global initiative aimed at providing recent college graduates with real-world job experiences. The program, which begins accepting applications on Feb. 11, 2022, will include around 30 Fellows who will receive mentorship, job coaching, and leadership training throughout the year. Successful participants will earn a Certificate of Completion and will be considered for future positions. The initiative aims to attract and retain top talent while enhancing PTC's organizational capabilities.

PTC Therapeutics presented an update on its commercial progress and R&D pipeline at the 40th J.P. Morgan Healthcare Conference on January 10, 2022. The company reported a 29% growth in net product revenue to $429 million in 2021, driven by its Duchenne muscular dystrophy (DMD) franchise. Key milestones for 2022 include expected results from clinical studies for Translarna and vatiquinone, alongside a financial guidance projecting revenues between $700 million and $750 million. The company holds approximately $773 million in cash as of year-end 2021.

PTC Therapeutics announced that Waylivra™ (volanesorsen) has received Category 1 classification from Brazil's CMED, making it the only treatment for familial chylomicronemia syndrome (FCS) available in the country. This classification recognizes its greater efficacy over current treatments and allows for international pricing. Furthermore, PTC submitted an application to ANVISA for Waylivra’s approval for familial partial lipodystrophy (FPL), potentially marking the first approved treatment for FPL globally. A decision from ANVISA is expected in the latter half of 2022.